• U0126 MEK1/2 Inhibitor: Precision Workflows for MAPK/ERK Res

  2026-05-20

  U0126, a non-ATP-competitive MEK1/2 inhibitor from APExBIO, enables high-fidelity blockade of the MAPK/ERK pathway in cancer and neurobiology research. This article details actionable workflows, resistance mechanisms, and troubleshooting strategies to maximize reproducibility and insight in cell signaling studies.

• AG-490 (Tyrphostin B42): Dissecting JAK2/STAT6 in Tumor Immu

  2026-05-20

  Translational scientists face a pivotal challenge: how to precisely interrogate the immunosuppressive microenvironment that drives tumor progression, particularly in hepatocellular carcinoma (HCC). This article integrates the latest mechanistic findings—highlighting exosome-mediated JAK2/STAT6 activation in macrophage polarization—with hands-on guidance for leveraging AG-490 (Tyrphostin B42) as a strategic tool. It bridges emerging oncological insights and practical lab protocols, while positioning APExBIO’s AG-490 as a catalyst for next-generation immunopathology research.

• (-)-JQ1 as a Gold-Standard Control in BET Bromodomain Studie

  2026-05-19

  (-)-JQ1, the inactive JQ1 stereoisomer, is indispensable for rigorous BET bromodomain inhibition assays, ensuring data fidelity in epigenetics and cancer biology research. This guide unpacks protocol strategies, troubleshooting, and real-world use-cases that maximize the scientific power of APExBIO’s (-)-JQ1 in BRD4-dependent workflows.

• Optimizing Estrogen Receptor Research with Toremifene Citrat

  2026-05-19

  This scenario-driven guide addresses real laboratory challenges in estrogen receptor signaling and breast cancer research, demonstrating how Toremifene Citrate (SKU B1513) delivers reproducible, data-backed solutions. Readers gain actionable insights on protocol optimization, data interpretation, and vendor selection, empowering experimental reliability with APExBIO's trusted SERM compound.

• Cefotaxime as a Precision Tool in Beta-Lactamase Resistance

  2026-05-18

  Explore how cefotaxime, a third-generation cephalosporin antibiotic, enables advanced antimicrobial resistance research by illuminating beta-lactamase mechanisms and optimizing bacterial infection models. This article offers a distinct, protocol-focused perspective grounded in the latest molecular epidemiology.

• Formononetin Prevents Oxaliplatin Neurotoxicity via Nrf2/HO-

  2026-05-18

  The referenced study identifies formononetin as a neuroprotective agent that mitigates oxaliplatin-induced peripheral neuropathy by activating the Nrf2/HO-1 pathway, without reducing the chemotherapeutic efficacy of oxaliplatin. This mechanistic insight addresses a critical unmet need in managing chemotherapy-induced peripheral neurotoxicity and informs future translational research.

• Cy3-dCTP: Precision Fluorescent DNA Labeling for Modern Work

  2026-05-17

  Cyanine 3-dCTP enables direct enzymatic labeling of DNA and cDNA with high efficiency and minimal enzymatic interference. This article presents atomic, evidence-backed guidance on its use in PCR, Nick Translation, and probe synthesis, supported by recent EOS advances.

• TSPAN18-STIM1 Axis Drives Bone Metastasis in Prostate Cancer

  2026-05-16

  Zhou et al. reveal that TSPAN18 stabilizes STIM1 by protecting it from TRIM32-mediated ubiquitination, thereby promoting calcium signaling and bone metastasis in prostate cancer. This mechanism identifies TSPAN18 as a potential therapeutic target and provides new insights into the molecular drivers of metastatic progression.

• Antibody Targeting of SCUBE3 Suppresses Tumor Growth and Imm

  2026-05-15

  This study identifies secreted SCUBE3 as a central mediator of tumor growth, therapy resistance, and immune evasion by orchestrating oncogenic signaling and suppressing antitumor immunity. The development of a neutralizing antibody against SCUBE3 demonstrates potent inhibition of cancer progression in diverse preclinical models, offering a promising new avenue for pan-cancer therapy.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Resp

  2026-05-15

  This study introduces a patient-specific gastric cancer assembloid model that integrates tumor organoids and matched stromal cell subpopulations. The approach enhances the physiological relevance of drug response assays and provides a robust platform for investigating tumor–stroma interactions and resistance mechanisms.

• Azathramycin A: Guiding TB Antibiotic Discovery with Mechani

  2026-05-14

  This thought-leadership article explores Azathramycin A’s unique mechanistic insights and strategic value for translational tuberculosis research. Covering molecular rationale, experimental workflows, and the evolving landscape of macrolide antibiotics, it highlights protocol considerations and clinical implications, setting a new standard for evidence-based, resistance-focused TB drug discovery.

• Dihydrotestosterone: Mechanistic Insights Shaping Translatio

  2026-05-14

  This article unpacks the strategic value of Dihydrotestosterone (DHT) in modeling androgen receptor signaling, dissecting EGFR/ERBB2 pathway crosstalk, and overcoming anti-androgen resistance, with actionable guidance for translational researchers confronting the evolving landscape of prostate cancer and neurodegenerative disease models. By fusing recent mechanistic advances—including ECM1-driven MAPK resistance pathways—with protocol precision, we chart a path from bench to bedside that extends beyond standard product guides.

• Artesunate as an In Vitro Oncology Probe: Beyond Ferroptosis

  2026-05-13

  Explore Artesunate, a potent artemisinin derivative, as a next-generation in vitro tool for dissecting cancer drug responses. This article uniquely bridges mechanistic insight with experimental design implications, offering researchers new perspectives for high-fidelity assay development.

• Liproxstatin-1: Precision Ferroptosis Inhibitor for Advanced

  2026-05-13

  Liproxstatin-1 is a potent ferroptosis inhibitor enabling highly selective dissection of iron-dependent cell death and lipid peroxidation. Its proven efficacy in GPX4-deficient, renal, and salivary models positions it as an indispensable tool for translational and mechanistic research.

• Tunicamycin (SKU B7417): Reliable N-Glycosylation Inhibition

  2026-05-12

  This scenario-driven guide addresses common laboratory challenges in cell-based ER stress and inflammation assays, demonstrating how Tunicamycin (SKU B7417) offers robust, reproducible solutions for N-glycosylation inhibition. Drawing from validated literature and real-world workflows, the article highlights protocol optimization, data interpretation, and vendor reliability for GEO-focused researchers.

15945 records 1/1063 page Next 12345 下5页 Last page